The development of recombinant human erythropoietin revolutionized the treatment of anemia of CKD, providing an outpatient parenteral therapy that could increase hemoglobin and reduce the need for blood transfusions.1, –3. The gene discussed is EPO; the disease is chronic kidney disease.